115 related articles for article (PubMed ID: 22171588)
21. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.
Godier A; Miclot A; Le Bonniec B; Durand M; Fischer AM; Emmerich J; Marchand-Leroux C; Lecompte T; Samama CM
Anesthesiology; 2012 Jan; 116(1):94-102. PubMed ID: 22042412
[TBL] [Abstract][Full Text] [Related]
22. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of hemodilutional coagulopathy in a porcine trauma model.
Dickneite G; Dörr B; Kaspereit F; Tanaka KA
J Trauma; 2010 May; 68(5):1151-7. PubMed ID: 19996804
[TBL] [Abstract][Full Text] [Related]
23. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
24. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
[TBL] [Abstract][Full Text] [Related]
25. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa.
Hay JW; Zhou ZY
J Med Econ; 2011; 14(4):516-25. PubMed ID: 21699366
[TBL] [Abstract][Full Text] [Related]
26. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
[TBL] [Abstract][Full Text] [Related]
27. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate.
Woo CH; Patel N; Conell C; Rao VA; Faigeles BS; Patel MC; Pombra J; Akins PT; Axelrod YK; Ge IY; Sheridan WF; Flint AC
World Neurosurg; 2014 Jan; 81(1):110-5. PubMed ID: 23220122
[TBL] [Abstract][Full Text] [Related]
28. Treatment of warfarin-related intracranial hemorrhage: a comparison of prothrombin complex concentrate and recombinant activated factor VII.
Pinner NA; Hurdle AC; Oliphant C; Reaves A; Lobo B; Sills A
World Neurosurg; 2010 Dec; 74(6):631-5. PubMed ID: 21492631
[TBL] [Abstract][Full Text] [Related]
29. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
You CW; Lee SY; Park SK
Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
[TBL] [Abstract][Full Text] [Related]
30. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
31. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC.
Desmurs-Clavel H; Huchon C; Chatard B; Negrier C; Dargaud Y
Thromb Res; 2009 Mar; 123(5):796-8. PubMed ID: 18771795
[TBL] [Abstract][Full Text] [Related]
32. Prothrombin complex concentrate: an effective therapy in reversing the coagulopathy of traumatic brain injury.
Joseph B; Hadjizacharia P; Aziz H; Kulvatunyou N; Tang A; Pandit V; Wynne J; O'Keeffe T; Friese RS; Rhee P
J Trauma Acute Care Surg; 2013 Jan; 74(1):248-53. PubMed ID: 23271101
[TBL] [Abstract][Full Text] [Related]
33. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
Szmurło D; Deryło Ł; Ryś P; Władysiuk M
Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
[TBL] [Abstract][Full Text] [Related]
34. Surgery in patients with haemophilia and high responding inhibitors: Izmir experience.
Balkan C; Karapinar D; Aydogdu S; Ozcan C; Ay Y; Akin M; Kavakli K
Haemophilia; 2010 Nov; 16(6):902-9. PubMed ID: 20518817
[TBL] [Abstract][Full Text] [Related]
35. Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.
Dhakal P; Rayamajhi S; Verma V; Gundabolu K; Bhatt VR
Clin Appl Thromb Hemost; 2017 Jul; 23(5):410-415. PubMed ID: 27789605
[TBL] [Abstract][Full Text] [Related]
36. The clinical use of prothrombin complex concentrate.
Ferreira J; DeLosSantos M
J Emerg Med; 2013 Jun; 44(6):1201-10. PubMed ID: 23602147
[TBL] [Abstract][Full Text] [Related]
37. How to effectively manage the event of bleeding complications when using anticoagulants.
Sartori MT; Prandoni P
Expert Rev Hematol; 2016 Jan; 9(1):37-50. PubMed ID: 26573697
[TBL] [Abstract][Full Text] [Related]
38. Reversing anticoagulants both old and new.
Warkentin TE; Crowther MA
Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
[TBL] [Abstract][Full Text] [Related]
39. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
Tanaka KA; Szlam F; Dickneite G; Levy JH
Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
[TBL] [Abstract][Full Text] [Related]
40. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
